scholarly journals In vitrothrombolytic efficacy of echogenic liposomes loaded with tissue plasminogen activator and octafluoropropane gas

2016 ◽  
Vol 62 (2) ◽  
pp. 517-538 ◽  
Author(s):  
Himanshu Shekhar ◽  
Kenneth B Bader ◽  
Shenwen Huang ◽  
Tao Peng ◽  
Shaoling Huang ◽  
...  
Stroke ◽  
2012 ◽  
Vol 43 (suppl_1) ◽  
Author(s):  
Tao Peng ◽  
George L Britton ◽  
Jaroslaw Aronowski ◽  
Davide Cattano ◽  
Melvin E Klegerman ◽  
...  

BACKGROUND: Ischemic stroke is the second most common cause of death worldwide and a major cause of disability. Intravenous (iv) tissue plasminogen activator (tPA) in combination with the neuroprotective gas, xenon (Xe), is a promising strategy for ischemic stroke treatment. However, Xe delivery by inhalation may reduce oxygen uptake and tPA activity. We have developed novel Xe-containing echogenic liposomes (Xe-ELIP). In this study, we investigated the therapeutic effect of Xe-ELIP in a rat embolic stroke model. METHODS: Xe-ELIP was prepared by the pressurized-freeze method. Thrombotic strokes were induced in male Sprague-Dawley rats (n=16) by injecting a 13mm long blood clot into the middle cerebral artery (MCA). In the treatment group, tPA (10mg/kg) was infused intravenously at 2 hours after the onset occlusion. Xe-ELIP was administrated into the common carotid artery just before iv tPA. Continuous wave ultrasound (1 MHz, 50% duty cycle, 0.5 W/cm 2 ) was applied to trigger Xe release from ELIP during the 5 min of Xe-ELIP administration. Behavioral tests (limb placement, grid walking and beam walking) were conducted three days after the thrombotic stroke. Two mm-thick coronal brain sections were cut and stained with TTC to determine infarct size. RESULTS: The thrombotic stroke control group without any treatment exhibited the largest damage and infarct size (17±5% of the whole brain); tPA treatment reduced the damage and the infarct size to 5.2±0.4% of (p=0.025 vs stroke). tPA treatment in combination with Xe-ELIP further reduced the infarct size to 1.5±0.4% (p=0.05 vs tPA group) ( Fig 1a, 1b). Behavioral deficit correlated with the infarct volume reduction. Regional blood flow velocity monitored by a laser Doppler flow meter was the same in both tPA and tPA+Xe-ELIP treatment groups. CONCLUSIONS: This study has demonstrated a significant neuroprotective effect of ELIP-encapsulated xenon released by application of 1 MHz ultrasound. Xe-ELIP can be used in combination with tPA without affecting tPA thrombolytic activity.


2012 ◽  
Vol 130 (4) ◽  
pp. 629-635 ◽  
Author(s):  
Susan T. Laing ◽  
Melanie R. Moody ◽  
Hyunggun Kim ◽  
Beverly Smulevitz ◽  
Shao-Ling Huang ◽  
...  

2007 ◽  
Vol 119 (6) ◽  
pp. 777-784 ◽  
Author(s):  
Susan D. Tiukinhoy-Laing ◽  
Shaoling Huang ◽  
Melvin Klegerman ◽  
Christy K. Holland ◽  
David D. McPherson

2007 ◽  
Vol 122 (5) ◽  
pp. 3052 ◽  
Author(s):  
Jason M. Meunier ◽  
Denise A. B. Smith ◽  
Christy K. Holland ◽  
Shao-Ling Huang ◽  
David D. McPherson ◽  
...  

Circulation ◽  
2007 ◽  
Vol 116 (suppl_16) ◽  
Author(s):  
Melanie Moody ◽  
Susan T Laing ◽  
Shaoling Huang ◽  
Hyunggun Kim ◽  
Beverly Smulevitz ◽  
...  

Background: Ultrasound has been shown to enhance thrombolysis when used in conjunction with a thrombolytic agent. We have loaded echogenic liposomes (ELIP) with tissue plasminogen activator (tPA) and shown that mechanical non-imaging 1 MHz ultrasound can enhance thrombolysis in an in vitro clot model. This study aimed to evaluate the efficacy of clinical Doppler ultrasound to enhance the thrombolytic effect of our tPA-ELIP. Materials and Methods: A standard reproducible whole blood porcine clot model was used. Clots were blotted dry, weighed, and placed in 10 ml fresh frozen porcine plasma. Clots were treated with tPA-ELIP with and without Doppler ultrasound (pulsed wave ultrasound, 6.6 MHz, 2 minute-treatment time). After 30 minutes, clots were similarly weighed. Data are reported as percent clot mass loss. Samples of the plasma were assayed for D-dimer levels. Results: Exposure of tPA-ELIP to clinical Doppler ultrasound enhanced thrombolysis (p=0.015 vs. tPA alone or Doppler ultrasound alone; Figure ). There was a trend towards higher D-dimer levels in the clots treated with tPA-ELIP + clinical Doppler ultrasound, corresponding to the higher percent clot mass loss seen in this treatment group. Conclusions: This study demonstrates the ability of clinical Doppler ultrasound to enhance the thrombolytic effect of our tPA-ELIP in an in vitro clot model. This demonstrates the potential to translate our novel thrombolytic technique of combining a thrombolytic-loaded contrast agent and ultrasound to patient care.


2007 ◽  
Vol 15 (2) ◽  
pp. 109-114 ◽  
Author(s):  
Susan D. Tiukinhoy-Laing ◽  
Kyle Buchanan ◽  
Devang Parikh ◽  
Shaoling Huang ◽  
Robert C. Macdonald ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document